EKF Diagnostics Holdings PLC
LSE:EKF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.8), the stock would be worth GBX29.13 (14% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | GBX25.5 |
0%
|
| 3-Year Average | 1.8 | GBX29.13 |
+14%
|
| 5-Year Average | 1.9 | GBX30.75 |
+21%
|
| Industry Average | 0 | GBX0.44 |
-98%
|
| Country Average | 0 | GBX0.36 |
-99%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
110.6m GBP | 1.6 | 52.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 9.4 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.1 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.6 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 2.2 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 3.7 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 4.7 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 2.2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 28.6 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 1.7 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.1 | 21.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 49 422.3 |
Other Multiples
EKF Diagnostics Holdings PLC
Glance View
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.
